0001493152-16-015280.txt : 20161118 0001493152-16-015280.hdr.sgml : 20161118 20161118171004 ACCESSION NUMBER: 0001493152-16-015280 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160419 FILED AS OF DATE: 20161118 DATE AS OF CHANGE: 20161118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CZIRR JAMES C CENTRAL INDEX KEY: 0001260641 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 162008513 MAIL ADDRESS: STREET 1: 425 JANISH DR CITY: SANDPOINT STATE: ID ZIP: 83864 4/A 1 form4a.xml X0306 4/A 2016-04-19 2016-04-21 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0001260641 CZIRR JAMES C C/O GALECTIN THERAPEUTICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD., SUITE 240 NORCROSS GA 30071 1 0 0 0 Common Stock 2016-04-19 4 S 0 33100 1.6802 D 3271909 I By 10X Fund, LP Common Stock 2016-04-20 4 S 0 11212 1.573 D 3260697 I By 10X Fund, LP Reflects weighted average price. Range of gross prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker. Reflects weighted average price. Range of gross prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker. The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein. /s/ James C. Czirr 2016-11-18